| abstract |
The present disclosure provides compounds according to Formula I, Formula II, as well as pharmaceutically acceptable salts, tautomers, and / or isotopologs thereof described in the present disclosure. The compound is an inhibitor of methionine adenosyltransferase isoform 2A (MAT2A). Also provided are pharmaceutical compositions for the treatment of cancer, including some cancers lacking the gene encoding methylthioadenosine phosphorylase (MTAP), and methods of using the compounds. |